Lyell Immunopharma, Inc.

The momentum for this stock is not very good. Lyell Immunopharma, Inc. is not a good value stock. Lyell Immunopharma, Inc. is a mediocre stock to choose.

News

Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Decreases By 7.9%

Ticker Report Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 7.9% in August

Zolmax Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…

SG Americas Securities LLC Trims Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Ticker Report SG Americas Securities LLC lowered its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 52.7% during the 2nd quarter, according to the company in its most recent Form 13F filing...\n more…

Lyell Immunopharma Announces Participation in September Investor Conferences

Globe Newswire SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...\n more…

Baillie Gifford & Co. Trims Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Ticker Report Baillie Gifford Co. cut its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 20.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The...\n more…

HC Wainwright Reaffirms "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL)

Zolmax Lyell Immunopharma (NASDAQ:LYEL - Get Free Report)s stock had its "neutral" rating restated by HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a...\n more…